Opendata, web and dolomites

RESOLVE SIGNED

tPA-Nanoconstructs for Treating Acute Ischemic Stroke: a Technical and Commercial Analysis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESOLVE project word cloud

Explore the words cloud of the RESOLVE project. It provides you a very rough idea of what is the project "RESOLVE" about.

profile    small    productivity    statistics    administration    societal    agents    stability    validating    causing    safely    neurological    neurotoxicity    disabilities    limitations    therapies    medical       induces    treatments    combination    pharmaceutical    biodegradation    complications    efficacy    suffering    total    sale    thrombolysis    occlusion    economic    molecule    re    estimate    longer    lasting    clot    cerebral    direct    designed    investing    clots    moved    diagnostics    worldwide    acute    fast    strokes    whereas    toxic    administered    approved    nano    25b    discoidal    deaths    death    portfolio    polymeric    protocols    50    therapeutic    blood    burden    thorough    nanoconstructs    fda    market    tech    patients    drug    secured    vessels    companies    safer    survivors    excretion    markets    people    lost    17m    damage    alleviate    stroke    20b    profiles    rationally    circulation    considerable    validated    faster    diminish    models    thrombolytic    ischemic    cohort    revolutionize    6m    fabrication    5m    tpa    dissolution    reports    emotional    brain    thrombectomy    commercial    dpns    indirect    patent    economical    interaction    business    clinically    healthcare   

Project "RESOLVE" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA 

Organization address
address: VIA MOREGO 30
city: GENOVA
postcode: 16163
website: www.iit.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) coordinator 150˙000.00

Map

 Project objective

Acute ischemic strokes result from the occlusion of cerebral vessels by blood clots causing neurological complications, brain damage and death. Based on WHO reports, stroke affects 17M people per year worldwide, with 6M deaths and 5M survivors suffering long-lasting disabilities. Recent statistics estimate an EU direct healthcare cost for stroke of €20B and indirect costs, due to disabilities and lost productivity, of €25B. The two current treatments – thrombolysis and thrombectomy – come with limitations and considerable side effects. Thrombolysis can be safely administered only to a small cohort of patients (about 5%) whereas thrombectomy induces disabilities in 50% of the cases. Moved by the societal, economical, and emotional burden associated with stroke, this proposal aims at developing and validating more effective and less toxic therapies via the combination of the clinically approved molecule tPA and rationally-designed, discoidal polymeric nanoconstructs (DPNs). As compared to tPA, the proposed thrombolytic nano-agents (tPA-DPNs) are expected to provide faster blood clot dissolution; safer administration profile; longer blood circulation and stability. On the technical side, tPA-DPNs will be re-designed to improve their biodegradation and excretion profiles; validated in FDA-recognized stroke models for neurotoxicity and therapeutic efficacy. On the commercial side, a patent portfolio covering the fabrication and utilization of tPA-DPNs will be secured, together with thorough market and business analyses. This will facilitate the interaction with pharmaceutical companies that are investing in the fast growing markets of high-tech drug delivery systems and stroke diagnostics and therapies. tPA-DPNs are expected to alleviate the economic burden on healthcare systems, increase the total sale of thrombolytic agents, revolutionize the medical protocols for stroke management, and diminish the societal and emotional impact of stroke.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESOLVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESOLVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More